Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Tim Wilsdon
Alzheimer's disease can't wait: the economic case for Europe to act now (Guest blog)
As we mark World Alzheimer's Month, attention is once again focused on the millions of people across Europe affected by Alzheimer's disease and other dementias. Alzheimer’s disease (AD) is at a turning point in Europe, with breakthroughs in therapies and diagnostics having the potential to transform approaches to care and management of the disease. Despite growing recognition of the need for comprehensive policy action to tackle AD, current efforts across Europe remain insufficient.
Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay?
1. Introduction Over the past decade, an increasing number of innovative medicines have obtained marketing authorisation in multiple indications. Predominantly, this trend is noticeable in the oncology space driven by research in immuno-oncology, specifically research in immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors, where drugs have demonstrated efficacy across a large number of indications. As described in depth by Lawlor et al.
Re: High drug prices are not justified by industry’s spending on research and development
Dear Editor, We note with interest the article by Angelis et al., arguing that high drug prices are not justified by industry’s spending on research and development (R&D). While we appreciate the call for more medically valuable and affordable innovations, there are areas where the evidence does not support the assertions in the paper. The article argues that prices do not reflect the R&D investment associated with new products.
The impact of price-based vaccine procurement programmes
Tim Wilsdon and Ryan Lawlor, Life Sciences Practice, CRA, examine how price-based models for vaccine are affecting coverage across the globe. The focus on the role of vaccines in addressing global health challenges has intensified in recent months in light of the spread of coronavirus. Vaccines have been shown to play a central role in the prevention and spread of many serious infectious diseases.
Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer
Although significant progress in the treatment of both common and rare cancers has been made in the past decade, there has been significant concern about the cost, and especially the value, of certain new oncology drugs. These concerns touch upon a number of issues regarding the price of these medicines, the value they deliver and the ability of healthcare systems to fund them [1].
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Tim
Contact Tim, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack